CellaVision AB: Interim report January - September 2013
(Thomson Reuters ONE) -
Strong sales and substantial improvement in earnings in the third quarter
January 1 - September 30, 2013
* Net sales were SEK 115.0 million (119.1).
* Operating profit was SEK 9.6 million (13.9).
* Result before tax was SEK 8.4 million (12.4).
* Earnings per share were SEK 0.26 (0.40).
* Cash and cash equivalents were SEK 42.6 million (52.6) at the end of the
period.
July 1 - September 30, 2013
* Net sales increased by 28 % to 45.1 million (35.3).
* Operating profit increased to SEK 10.7 million (4.0).
* Profit before tax increased to SEK 10.4 million (3.0).
* Earnings per share increased to SEK 0.33 (0.16).
Significant events during the third quarter
* The first major orders of the new DI-60 were delivered to Sysmex Europe and
Japan.
Significant events after the period close
* CellaVision signs a Term Sheet with the Chinese company Mindray for
distribution of CellaVision's products in above all China but also on other
growth markets.
Key Ratios
(SEK million) Jul-Sep 2013 Jul-Sep 2012 Jan-Sep 2013 Jan-Sep 2012 Full year
2012
Net sales 45.1 35.3 115.0 119.1 169.5
Gross profit or loss 27.5 22.6 72.8 78.4 110.1
Operating profit 10.7 4.0 9.6 13.9 20.7
Operating margin. % 23.7 11.3 8.4 11.7 12.2
Profit/loss before tax 10.4 3.0 8.4 12.4 18.6
Total cash flow for the 1.5 5.2 -3.6 -4.2 -10.6
period
Comments by CellaVision's CEO Yvonne Mårtensson:
"It is satisfying to see a strong growth in our sales for the third quarter.
Sales rose by 28 % compared with the same period in 2012 and operating profit
increased to SEK 10.7 million. Thus we are winning back most of the sales we
lost earlier this year.
During the quarter we delivered the first major orders of the new integrated
product DI-60 to Sysmex in Europe and Japan. The sale indicates a need for fully
automated product lines at large laboratories and confirms our technology
investments. We estimate that sales of the product will also get under way in
the USA before the end of the year.
Our sales in China are driving the continued positive development in the Asia
Pacific region. In accordance with our geographical expansion strategy we are
currently evaluating the Chinese company Mindray as a potential distribution
partner, above all in China but also on other growth markets. Our ambition is to
have an agreement ready before the end of the year.
In Europe sales improved during the quarter and in the USA we assess that the
downturn in demand for our products is approaching a turning point. Through our
partnership initiatives and product development we will stand strong when the
market turns fully. The interest in our products continues to be strong and our
future growth will be driven by growing rationalization requirements in health
care."
Questions concerning the report can be addressed to:
Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46 708 33 77 82. Email: yvonne.martensson(at)cellavision.se
Magnus Blixt, CFO, CellaVision AB
Tel: +46 708 33 81 68. Email: magnus.blixt(at)cellavision.se
CellaVision AB Interim report January ? September 2013:
http://hugin.info/132164/R/1737553/582715.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1737553]
Unternehmensinformation / Kurzprofil:
Datum: 24.10.2013 - 08:21 Uhr
Sprache: Deutsch
News-ID 308895
Anzahl Zeichen: 4490
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 146 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision AB: Interim report January - September 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
